Registry for the Management of Helicobacter Pylori Infection in Shandong Province

Summary

Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, with differing efficacy outcomes largely attributable to increasing bacterial antibiotic resistance. Furthermore, multiple factors influence the efficacy of H. pylori eradication, including smoking, body surface area, CYP2C19 gene polymorphisms, patient compliance, and regional variations.

Therefore, to systematically evaluate the efficacy and safety of different treatment regimens alongside the cost-effectiveness of various therapeutic strategies, and to conduct ongoing critical analysis of clinical practice, this study proposes a long-term investigation of real-world clinical practice through a non-interventional cohort study registry. This will assess the effectiveness, safety, and temporal trends of different H. pylori infection treatment regimens, providing real-time evidence to support clinical practice.

Conditions

• HELICOBACTER PYLORI INFECTIONS

Interventions

OTHER

Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.

Doctors prescribe Helicobacter pylori treatment regimens for patients based on current guidelines and consensus statements, tailored to individual circumstance, not involve any intervention procedure.

Sponsors & Collaborators

• Yueyue Li

  lead OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Feicheng People's Hospital

  collaborator UNKNOWN

• Binzhou Maternal and Child Health Hospital

  collaborator UNKNOWN

• Jinxiang County People's Hospital

  collaborator UNKNOWN

• The People's Hospital of Jimo

  collaborator UNKNOWN

• Zibo Maternal and Child Health Hospital

  collaborator OTHER

• Yantai Penglai Traditional Chinese Medicine Hospital

  collaborator UNKNOWN

• Zaozhuang Municipal Hospital

  collaborator OTHER

• Linyi Yizhou Hospital

  collaborator UNKNOWN

• Taierzhuang District People's Hospital

  collaborator OTHER

• Shandong University of Traditional Chinese Medicine

  collaborator OTHER

• Yuncheng Traditional Chinese Medicine Hospital

  collaborator OTHER

• Caoxian County Hospital

  collaborator UNKNOWN

• Qihe County People's Hospital

  collaborator UNKNOWN

• University Town Hospital, Afiliated Hospital of Shandong University of Traditional Chinese Medicine

  collaborator UNKNOWN

• Dezhou Hospital Qilu Hospital of Shandong University

  collaborator OTHER

• The 2nd People's Hospital of Dongying City

  collaborator UNKNOWN

• Zhangdian District Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Yantai Zhifu Hospital

  collaborator UNKNOWN

• Inner Mongolia Autonomous Region International Mongolian Medicine Hospital

  collaborator UNKNOWN

• Hohhot Second Hospital

  collaborator UNKNOWN

• Guanxian People's Hospital

  collaborator UNKNOWN

• Longkou People's Hospital

  collaborator UNKNOWN

• Linshu County Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-02-01

Primary Completion

2035-11-01

Completion

2035-11-30

Countries

• China

Study Locations